This is not the most recent version of the article. View current version (3 FEB 2016)

Intervention Protocol

Idiotype vaccination for Non-Hodgkin lymphoma

  1. Vera Ossendorf1,*,
  2. Oliver Cornely2,
  3. Andreas Draube2,
  4. Ina Monsef3,
  5. Andreas Engert3,
  6. Nicole Skoetz3

Editorial Group: Cochrane Haematological Malignancies Group

Published Online: 19 JAN 2011

DOI: 10.1002/14651858.CD008964


How to Cite

Ossendorf V, Cornely O, Draube A, Monsef I, Engert A, Skoetz N. Idiotype vaccination for Non-Hodgkin lymphoma (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 1. Art. No.: CD008964. DOI: 10.1002/14651858.CD008964.

Author Information

  1. 1

    Medical Division, Clinical Trials Center Cologne, Cologne, Germany

  2. 2

    University Hospital of Cologne, Department of Internal Medicine 1, Center of Integrated Oncology Köln Bonn, Cologne, Germany

  3. 3

    University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany

*Vera Ossendorf, Clinical Trials Center Cologne, Medical Division, Herderstrasse 52, Cologne, 50931, Germany. vera.ossendorf@zks-koeln.de.

Publication History

  1. Publication Status: New
  2. Published Online: 19 JAN 2011

SEARCH

This is not the most recent version of the article. View current version (03 FEB 2016)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

In order to evaluate the therapeutical benefit of idiotype vaccination in the treatment of NHL we will particularly analyse overall survival (OS) as the primary endpoint; as well as progression-free survival (PFS), response rate, treatment-related mortality, adverse events and quality of life as secondary endpoints. We will analyse these outcome parameters critically and systematically with respect to different vaccine formulations, dosages or time schedules in the experimental arm and placebo or no other treatment in the control arm.